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ABSTRACT
Mitochondrial dysfunction is associated with several clinical manifestations including diabetesmellitus (DM), neurological disorders,
renal and hepatic diseases, and myopathy. Although mitochondrial dysfunction is associated with increased bone resorption and
decreased bone formation inmousemodels, effects of alterations inmitochondrial function on bone remodeling andmass have not
been investigated in humans. We recruited 45 carriers (29 females, 16 males) with the m.3243A>G mutation and healthy controls
matched for gender, age, height, and menopausal status. DXA and HRpQCT scans were performed, and bone turnover markers
(BTMs) P1NP and CTX were measured. Cases and controls were well matched except for body weight, which was lower in cases
(63.6 18.1 kg versus 74.6 14.8 kg, p< 0.01), andmanifest DMwas present in 25 of 45 cases (none in controls). Bone scans showed
lower BMD at the lumbar spine, total hip, and femoral neck in cases. Mean lumbar spine, total hip, and femoral neck T-scores were
–1.5, –1.3, and –1.6 in cases, respectively, and –0.8, –0.3, and –0.7 in controls (all p< 0.05). The m.3243A>Gmutation was associated
with lower BMD, cortical but not trabecular density, cortical thickness, and estimated bone strength. Furthermore, BTMs were lower
in the m.3243A>G group before but not after adjustment for DM. The mitochondrial point mutation m.3243A>G was associated
with decreased bone mass and strength. Although the coexistence of DMmay have inﬂuenced bone turnover, the bone phenotype
observed in m.3243A>G cases appeared to mirror age-related deterioration in bone, suggesting that mitochondrial dysfunction
may cause a premature aging of bone. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
The mitochondrion is the principal site of generation ofadenosine triphosphate (ATP) and reactive oxygen species
(ROS), and it is generally agreed that molecular damage caused
by ROS is central in the pathogenesis of human aging and
contributes to the accompanying gradual loss of bone mass.(1,2)
Clinical data corroborating potentially deleterious effects of
mitochondrial dysfunction on bone mass and fracture risk as
observed in osteoporosis are limited.
Several animal studies support causative roles of mitochon-
drial dysfunction on bone metabolism. Mice with mitochondrial
dysfunction due to accumulation of mutations in mitochondrial
DNA (mDNA) display premature onset of age-related disorders,
including reduced bone mineral density (BMD) and multiple
compression fractures of the spine.(3) Depletion of intracellular
ATP increases osteoclast resorption activity and apoptosis and
inhibits bone formation in mice, supporting that intracellular
ATP levels regulate bone remodeling.(4) Furthermore, ROS
increases bone resorption by promoting receptor activator of
nuclear factor kappa-B ligand (RANKL)-induced proliferation,
differentiation, and lifespan of osteoclasts,(5) whereas oxidative
stress reduces osteoblast differentiation and subsequently
bone formation, by inhibition of the Wnt/b-catenin signaling
pathway.(6) In addition, increased oxidative stress in osteocytes
speciﬁcally increases osteoclast resorption and decreases bone
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formation due to increased expression of RANKL and the
Wnt-pathway inhibitor sclerostin.(7)
The clinical phenotypes of mitochondrial diseases in humans
may include several conditions, including but not restricted to
impaired growth, myopathy, neurological deﬁcits, and liver and
kidney diseases.(8) Severe osteoporosis has been reported in a
single case of a young man with an mDNA deletion,(9) but it
remains unknown if mitochondrial dysfunction inﬂuences bone
remodeling in humans.
The m.3234A>G is the most common mitochondrial point
mutation (3.5 per 100,000).(8) Carriers of the m.3234A>Gmay be
asymptomatic or develop speciﬁc clinical phenotypes including
mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes (MELAS) andmaternally inherited diabetesmellitus
(DM) and deafness (MIDD).(10) Although infrequent, hypopara-
thyroidism has been reported in m.3234A>G carriers.(11–13)
Hypoparathyroidism may increase bone mass due to lower
bone turnover,(14) but accounts of bone mass in carriers
of m.3234A>G mutations are absent. Exercise, disuse, and
age-related changes in muscle and bone mass are correlated in
humans, and low BMD has been reported in patients with
myopathy.(15,16) Although BMD is lower in type 1 DM (T1D) and
normal or increased in type 2 DM (T2D), bone turnover is lower
in both T1D and T2D.(17,18) Mitochondrial DM is generally
explained by decreased insulin secretory capacity,(19) suggest-
ing that the bone phenotype of individuals with m.3243A>G
could resemble that observed in T1D.
Although mitochondrial dysfunction appears to have signiﬁ-
cant impact on bone remodeling in mice, effects on human
bone turnover, mass, and structure are unknown. The aim of
this case-control study was to characterize bone turnover,
mass, structure, and estimated strength in subjects carrying
the m.3243A>G mitochondrial mutation.
Subjects and Methods
Design, setting, and participants
This cross-sectional study was conducted between June 2013
and June 2015. The study population consisted of 45 adult
subjects carrying the mitochondrial point mutation m.3243A>G
recruited from a Danish cohort of m.3243A>G–positive subjects
from 25 families. These families included 79 individuals, three of
whomwere excluded due to pregnancy (n¼ 1), cancer (n¼ 1), or
coexistence of a PHEXmutation (n¼ 1). Twelve individuals were
below the age of 18 years, and 19 declined participation.
Forty-ﬁve control subjects were included from a cohort of 499
healthy individuals participating in a separate study aimed at
establishing HRpQCT reference date in the adult Danish
population. The participants in the HRpQCT study were
recruited in 2010 to 2011 using population listings in the
municipality of Odense.(20) Each m.3243A>G positive subject
was matched with a control subject from this cohort with regard
to gender, age, height, andmenopausal status (nomenstruation
for at least 6 months).
Examinations and scans were performed at Odense University
Hospital. Information on lifestyle, comorbidities, and treatment
was retrieved by interview and a structured questionnaire. Body
weight was measured with participants wearing casual indoors
clothing and barefoot to the nearest 0.1 kg on a Seca model 708
scale (Seca, Hamburg, Germany). Body height was measured to
the nearest 0.1 cm on a wall-mounted Harpenden stadiometer
(Holtain Ltd., Crymich, UK).
All participants provided informed consent, and the studywas
performed according to the guidelines from the Declaration of
Helsinki. The Regional Scientiﬁc Ethical Committees for Southern
Denmark approved both investigations (ID S-20100112 and ID
S-20090069).
Genetic investigations
DNA extractions were carried out using the QIAamp DNAMini Kit
(Qiagen GmbH, Hilden, Germany), using the manufacturer’s
protocol. An allele-speciﬁc polymerase chain reaction (PCR)
assay was used for the detection of the m.3243A>G mutation.
Two sets of primers were used in one reaction tube: 3014L
(forward), GTGCAGCCGCTA TTAAAGGT, and 3262HM17 (reverse),
TTTTATGCG ATTACCGCGCC harboring two mismatches, which
allow for a selective ampliﬁcation of a 249-bp product if
the m.3243A>G mutation is present. A control 614-bp product
was co-ampliﬁed using the primers 5289 to 5309 (forward)
and 5903 to 5584 (reverse). PCR reactions were carried out using
GoTaq (Promega, WI, USA) on an ABI 2720 (Thermo Fisher,
MA, USA).
DXA, HRpQCT, and biochemical analysis
Areal BMD (aBMD) at the lumbar spine (L1–L4), total hip, femoral
neck (all participants), and whole-body composition (cases only)
were measured using dual-energy X-ray absorptiometry (DXA)
(Hologic Discovery, Waltham, MA, USA). Bone geometry,
volumetric BMD (vBMD), and microarchitecture were assessed
using a HRpQCT system (Xtreme CT; Scanco Medical AG,
Brüttisellen, Switzerland) as described.(21) The quality of the
HRpQCT scans of the forearm was unacceptable due to motion
artifacts (grade <3) in ﬁve of the participants, and these images
and those from matching controls were excluded from the
analyses.
Blood samples were drawn between 7:30 a.m. and 10:00 a.m.
in the fasting state and stored at –80°C until measurement of
serumprocollagen type I amino-terminal propeptide (P1NP) and
C-telopeptide of type I collagen (CTX) by chemiluminescence
method. The samples were analyzed in a single step with the
same batch of the reagents and assay.(22)
Statistical analyses
Data were expressed as mean standard deviation, median
(interquartile range [IQR]), or numbers as appropriate. Normality
was evaluated using normal probability plots. m.3243A>
G–positive subjects and controls were compared using chi
square test for categorical variables and unpaired Student’s t
test or Mann-Whitney U test for normally distributed or
nonparametric data, respectively. Differences in bone mass,
structure, and strength in m.3243A>G–positive subjects and
controls were presented graphically as mean percentage
differences. These relationships were further investigated
in three regression models. The ﬁrst model included
mutation status as the only independent variable; the
second model included mutation status, body weight, age,
and gender as independent variables. In addition, the
third model also included DM status. Logarithmic transfor-
mation was applied if variables were not normally distrib-
uted. Statistical analyses were performed using STATA
statistical package version 14 (StataCorp LP, College Station,
TX, USA).
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Results
General characteristics of study participants
Characteristics of m.3243A>G subjects and controls are
presented in Table 1. Gender, age, body height, fracture history,
ethnicity, smoking status (present smoker or nonsmoker),
alcohol consumption (dichotomized as intake of more than 14
units per week or less), menopausal status, age at menopause,
and length of radius and tibia did not differ between the
groups. However, mean body weight and BMI were 11.0 kg and
3.8 kg/m2 lower in the m.3243A>G group. The mean BMI of
the m.3243A>G group was within the normal range (BMI
23.0 5.3 kg/m2), but included eight individuals with a BMD
<18.5 kg/m2, whereas the control subjects were slightly
overweight (BMI 26.8 4.1 kg/m2). Furthermore, calcium intake
(dietary and supplement combined) was higher and use of
vitamin D supplements were prevalent in the m.3243A>G
subjects.
Case-specific characteristics
Twenty-ﬁve of them.3243A>G subjects hadmanifest DM and 31
reported hearing impairment (HI). None of the cases were
known to have hepatic disease. Two cases had impaired renal
function (creatinine>200mmol/L). Those with DM were treated
using several types of antidiabetic drugs or dietary restrictions,
but none of the diabetics were treated with peroxisome
proliferator-activated receptor gamma agonists or metformin.
Table 2 presents the m.3243A>G group stratiﬁed according to
DM status. Cases with DM were more likely to report HI.
Furthermore, body weight, but not body fat percentage, was
lower in mutation carriers with DM.
aBMD
aBMD of the lumbar spine, total hip, and femoral neck were
lower in cases than controls (Table 1, Fig. 1), and femoral neck
BMDwas lower in cases with DM compared to thosewithout DM
(Table 2). T-scores of the lumbar spine, total hip, and femoral
neck in cases were –1.54 1.27, –1.27 1.20, and –1.63 1.17,
respectively, and –0.80 1.22, –0.30 0.99, and –0.72 0.97,
respectively, in controls (all p< 0.05). The m.3243A>Gmutation
Table 1. General Characteristics of the Study Population
m.3243A>G
(n¼ 45)
Control
(n¼ 45)
Gender (male/female), n 16/29 16/29
Age (years) 47.6 15.2 47.8 14.4
Body weight (kg) 63.6 18.1 74.6 14.8
Body height (cm) 165.4 9.3 166.4 8.4
Body mass index (kg/m2) 21.4
(20.1–25.0)
26.3
(23.9–28.7)
Any previous fracture (yes/no), n 15/30 13/32
Diabetes status (DM/non-DM), n 25/20 0/45
Hearing impairment (HI/non-HI), n 31/14 0/45
Ethnicity (white/Middle Eastern/
Hispanic), n
43/1/1 45/0/0
Current smoking (yes/no), n 11/34 10/35
Alcohol consumption (yes/no), na 1/44 5/39
Menopause (post/pre/male), n 16/13/16 16/13/16
Age at menopause (years) 48.2 6.8 48.4 3.6
Daily calcium intake (mg) 1300
(775–1700)
600
(400–850)
Vitamin D supplement (yes/no/
unknown), n
29/16/0 4/40/1
Radius length (cm) 24.7 2.0 25.2 2.2
Tibia length (cm) 36 (34–38) 36 (34–38)
Total spine aBMD (g/cm2) 0.89 0.14 0.97 0.13
Total hip aBMD (g/cm2) 0.81 0.16 0.94 0.13
Femoral neck aBMD (g/cm2) 0.68 0.16 0.80 0.13
N-terminal propeptide of type 1
procollagen (mg/L)
45.3 23.4 57.8 25.1
C-terminal telopeptide of type 1
collagen (mg/L)
0.41 0.31 0.55 0.30
Values are mean SD, median (interquartile range), or n.
aYes: 14 units of alcohol per week.
p< 0.05.
p< 0.01.
Table 2. Characteristics of Cases Stratiﬁed According to Coexis-
tence of DM
DM
(n¼ 25)
non-DM
(n¼ 20)
Gender (male/female), n 8/17 8/12
Age (years) 49.7 14.0 44.9 16.5
Body weight (kg) 55.0
(51.9–64.1)
70.1
(57.6–78.2)
Body height (cm) 163.5 8.8 167.8 9.7
Body mass index (BMI) (kg/m2) 21.1
(19.2–23.3)
24.8
(20.8–27.3)
Any previous fracture (yes/no), n 11/14 4/16
Hearing impairment (HI/non-HI), n 22/3 9/11
Current smoking (yes/no), n 5/20 6/14
Alcohol consumption (yes/no), na 1/24 0/20
Menopause (post/pre/male), n 8/9/8 8/4/9
Age at menopause (years) 48.2 6.8 48.4 3.6
Daily calcium intake (mg) 1350
(900–1925)
1225
(762.5–1600)
Vitamin D supplement (yes/no/
unknown), n
18/7/0 11/9/0
Radius length (cm) 24.0
(23.0–26.0)
24.5
(23.3–26.5)
Tibia length (cm) 35.4 2.7 37.1 3.1
Whole body fat (kg) 18.5
(13.9–22.0)
22.28
(14.9–29.3)
Whole body lean and BMC (kg) 36.7
(32.5–46.2)
43.76
(41.8–52.2)
Whole body mass (kg) 55.8
(49.9–67.0)
71.02
(58.7–79.4)
Whole body fat percentage (%) 31.8 7.9 32.2 10.0
Vitamin D (nmol/L) 93.2 7.6 73.6 6.8
Total spine aBMD (g/cm2) 0.86 0.13 0.90 0.15
Total hip aBMD (g/cm2) 0.78 0.16 0.85 0.16
Femoral neck aBMD (g/cm2) 0.64 0.13 0.73 0.17
N-terminal propeptide of type 1
procollagen (mg/L)
34.12 1.08 48.91 1.11
C-terminal telopeptide of type 1
collagen (mg/L)
0.23 1.16 0.461.16
Values are mean SD, median (interquartile range), or n.
aYes: 14 units of alcohol per week.
p< 0.05.
p< 0.01.
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was associated with lower aBMD in the unadjusted and the
gender, age, and weight-adjusted models (Table 3), but
only signiﬁcantly associated with lower total hip BMD after
adjustment for DM. DM was not associated with aBMD in
regression models.
Bone geometry
Total and trabecular bone areas in radius, but not tibia, were
larger in the m.3243A>G group in all models with the exception
of total bone area in the unadjusted model (Table 4, Fig. 1). The
cortical areas of both the radius and tibia were smaller in the
m.3243A>G group in all regression models.
vBMD
The presence of m.3243A>G mutation was associated with
lower total vBMD, cortical vBMD, and trabecular vBMD in the
radius in all models (Table 4). Both total and trabecular tibial
vBMD were lower in the m.3243A>G group before and after
adjustment for weight, gender, and age, and total vBMD
remained lower after adjustment for DM status. Tibial cortical
vBMD was only associated with mutation status after adjust-
ment for weight, gender, and age (Table 4).
Bone microarchitecture
The m.3243A>G was associated with a lower ratio between
trabecular bone volume and tissue volume in both radius and
tibia, but this was not signiﬁcant in tibia after adjustment for DM
status (Table 4, Fig. 1). The m.3243A>Gmutation was associated
with lower trabecular number in the unadjusted model and the
fully adjusted model, but trabecular thickness was not
associated with mutation status in radius and tibia. Cortical
thickness was lower in m.3243A>G carriers in all models in both
radius and tibia, and radial cortical porosity was higher in the
m.3243A>G group in the fully adjusted model (Table 4).
Estimated bone strength
The m.3243A>G mutation was associated with lower estimated
bone stiffness and failure loads in tibia in all models (Table 4,
Fig. 1). Conversely, m.3243A>G was associated with estimated
Fig. 1. Comparison of DXA and HRpQCT results in cases and controls, expressed as mean percentage difference.
Table 3. Association Between aBMD and Mutation Status
(n¼ 90)
Model 1 Model 2 Model 3
Total spine aBMD (g/cm2)
m.3243A>G (þ/–) –0.081 –0.060 –0.062
DM status (þ/–)a 0.005
Total hip aBMD (g/cm2)
m.3243A>G (þ/–) –0.125 –0.068 –0.065
DM status (þ/–)a –0.007
Femoral neck aBMD (g/cm2)
m.3243A>G (þ/–) –0.113 –0.079 –0.058
DM status (þ/–)a –0.042
Model 1: m.3243A>>G status as independent variable. Model
2: m.3243A>G status, weight, age and gender as independent variables.
Model 3: m.3243A>G status, weight, age, gender, and DM status as
independent variables.
aIndependent effect of diabetes.
p< 0.05.
p< 0.01.
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radial bone stiffness and failure loads after adjustment for gender,
age, and weight, but not after further adjustment for DM.
Biochemical markers of bone turnover
Bone turnover markers (BTMs) (CTX and P1NP) were lower in the
m.3243A>G group than in controls (Table 2). However, only
P1NP was lower in cases after adjustment for gender, age, and
weight in the regression analyses, and mutation status was not
associated with the BTMs after adjustments for DM (Table 5).
Both BTMs were lower in individuals with manifest DM in the
latter model. Among m.3243A>G carriers, BTMs were lower in
those with DM (Table 2).
Table 4. Association Between HRpQCT-Derived Measures of Bone Mass, Structure, and Strength, and Mutation Status
Radius (n¼ 80) Tibia (n¼ 90)
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Bone geometry
Total bone area (mm2)
m.3243A>G (þ/–) 26.545 33.289 39.393 21.656 14.876 22.216
DM status (þ/–)a –12.383 –14.546
Cortical area (mm2)
m.3243A>G (þ/–) –8.658 –7.941 –8.641 –25.413 –20.669 –18.580
DM status (þ/–)a 1.421 –4.139
Trabecular area (mm2)
m.3243A>G (þ/–) 32.678 38.430 44.759 0.696 32.211 38.481
DM status (þ/–)a –12.839 –12.425
Cortical perimeter (mm)
m.3243A>G (þ/–) 3.825 4.888 5.288 –2.080 0.705 1.217
DM status (þ/–)a –0.811 –1.016
Volumetric bone mineral density
Total bone density (mg/cm3)
m.3243A>G (þ/–) –65.035 –64.043 –73.005 –42.440 –37.281 –37.291
DM status (þ/–)a 18.182 0.021
Cortical density (mg/cm3)
m.3243A>G (þ/–) –46.438 –50.672 –68.185 –20.427 –26.588 –26.038
DM status (þ/–)a 35.528 –1.091
Trabecular density (mg/cm3)
m.3243A>G (þ/–) –20.448 –18.607 –22.299 –23.569 –15.647 –15.579
DM status (þ/–)a 7.489 –0.135
Bone microarchitecture
Trabecular bone volume/tissue volume
m.3243A>G (þ/–) –0.018 –0.017 –0.018 –0.020 –0.013 –0.013
DM status (þ/–)a 0.004 –0.000
Trabecular number (1/mm)
m.3243A>G (þ/–) –0.193 –0.159 –0.205 –0.192 –0.078 –0.185
DM status (þ/–)a 0.093 0.211
Trabecular thickness (mm)
m.3243A>G (þ/–) –0.002 –0.003 –0.002 –0.003 –0.003 0.002
DM status (þ/–)a –0.000 –0.010
Direct cortical thickness (mm)
m.3243A>G (þ/–) –0.143 –0.143 –0.145 –0.180 –0.166 –0.147
DM status (þ/–)a 0.004 –0.037
Cortical porosity (%)
m.3243A>G (þ/–) 1.121 1.167 1.314 1.073 1.114 1.133
DM status (þ/–)a 0.705 0.951
Estimated bone strength
Total bone stiffness (kN/mm)
m.3243A>G (þ/–) –9,032.7 –7,293.4 –6,839.1 –36,735.9 –25,016.3 –16,954.7
DM status (þ/–)a –891.9 –16,236.8
Estimated failure load (kN)
m.3243A>G (þ/–) –451.1 –356.7 –351.3 –1,836.6 –1,234.9 –903.2
DM status (þ/–)a –10.6 –668.0
Model 1: regression with m.3243A>G status as independent variables. Model 2: m.3243A>G status, weight, age, and gender as independent variables.
Model 3: m.3243A>G status, weight, age, gender, and DM status as independent variables.
aIndependent effect of diabetes.
p < 0.05.
p < 0.01.
Journal of Bone and Mineral Research M.3243A>G AND LOWER BMD, THINNER CORTICES, AND REDUCED BONE STRENGTH 2045
Discussion
We have demonstrated that bonemass, structure, and estimated
strength are compromised in carriers of m.3243A>G mitochon-
drial mutations. Additionally, BTMs were lower in carriers with
DM. To our knowledge, this is the ﬁrst comprehensive investiga-
tion of bone composition and turnover in individuals with a
mitochondrial mutation.
The m.3243A>G mutation causes mitochondrial dysfunction
and enhances oxidative stress, which is considered part of the
pathogenesis of DM and other manifestations of mitochondrial
disease.(23) Previous investigations of bone status in monogenic
mitochondrial disorder are lacking. Negative correlations
between BMD and oxidative stress and oxidative damage
have been observed in postmenopausal women,(24,25) support-
ing that the bone phenotype observed in our investigation
is explained by mitochondrial dysfunction. With age, vBMD,
cortical thickness, and trabecular number decline, cortical
porosity increases, and estimated bone strength regresses,(21)
which is largely compatible with the pattern of differences
among the carriers of m.3243A>G mutation and healthy
individuals observed in our study. Although speculative, this
could indicate that the m.3243A>G bone phenotype exemplify
premature bone aging.
Nearly all carriers of the m.3243A>G develop impaired
glucose tolerance or DM before the age of 70 years,(26) and it is
generally agreed that mitochondrial DM primarily is caused
by impaired glucose-stimulated insulin secretion.(26) Increased
heteroplasmy is associated with earlier debut of DM in carriers
of m.3243A>G.(27) Therefore, the bone phenotype observed in
mutation carriers with DM may illustrate the effects of severe
forms of mitochondrial dysfunction and DM. This notion is
supported by a higher prevalence of HI and lower body weight
in m.3243A>G with DM, indicating that these individuals had a
higher level of mitochondrial dysfunction.
The present study shows that the bone phenotype observed
in m.3243A>G carriers, in most aspects differ from that seen
in healthy controls, and appear to share similarities with the
bone phenotype reported in T1D, which includes decreased
cortical bone thickness and density as well as lower trabecular
vBMD.(22,28) With respect to bone turnover, the regression
analyses showed that bone turnover appeared to be preserved
in nondiabetic but lower in diabetic mutation carriers. However,
the relatively small size of the study population refrained us from
assessing BTMs at different age ranges in mutation carriers and
controls. Therefore, we cannot exclude the possibility that
bone turnover is lower in elderly mutation carriers. However,
because heteroplasmy levels were not assessed in our study, we
were unable to investigate whether the degree of mitochondrial
dysfunction, assessed using heteroplasmy levels as a surrogate
marker, was associated with any of the available measures of
bone mass, structure, or turnover.
BMD and body weight are closely associated, and the
difference in weight between cases and controls probably
inﬂuenced the results of this study.(29,30) Obese adults have
higher BMD, thicker and denser cortices, and higher trabecular
number than non-obese adults,(31,32) and these differences
are mainly present in tibia and not radius, suggesting that the
effects of body weight are explained by positive effects of
mechanical loading. When comparing our study with studies
of the effect of obesity on BMD it seems that weight has a
disproportionately larger impact on BMD in our study.(31,33)
Furthermore, with trabecular number and CTX as exceptions, we
observed that associations between m.3243A>G and bone
parameters remained signiﬁcant after adjustment for weight,
gender, and age. Taken together, this suggests that the weight
difference cannot explain the differences in the bone phenotype
between cases and controls in our study.
Mitochondrial myopathy may cause varying degrees of
exercise intolerance, fatigue, myalgia, and a general sense of
weakness,(34) and lower levels of habitual physical activity have
been reported in mitochondrial patients.(35) Physical activity is
directly correlated with bone mass; therefore, mitochondria-
related myopathy could affect bone mass and structure.(36,37)
Unfortunately, data on physical activity were not recorded in the
present investigation, which excluded the possibility of
evaluating whether differences in bone status and BTMs
between m.3243A>G carriers and controls were related to
physical activity.
Use of calcium and vitamin D supplements were higher in
the m.3243A>G carriers, which may be explained by higher
contact with healthcare services in cases versus controls. These
supplements could be beneﬁcial to the bone status of the cases,
and any negative effect of m.3243A>G might thus be under-
estimated. Although unsubstantiated, subclinical disturbances
in the calcium metabolism such as hypoparathyroidism could
interfere with bone metabolism in cases with m.3243A>G.
The prevalence of hypoparathyroidism was 6% among 226
individuals with Kearns-Sayre syndrome (KSS) (mitochondrial
encephalomyopathies with early onset, caused by deletions of
mDNA), but similar data is not available for m.3243A>G.(38)
Although the present investigation shows that mitochondrial
dysfunction due to m.3243A>G mutation may have deleterious
effects on bone, the mechanisms linking the mutation and
mitochondrial dysfunction to the bone phenotype remains to
be determined. Figure 2 presents some of the mechanisms,
which may link mitochondrial dysfunction to the bone
phenotype. Mitochondrial dysfunction including ATP deﬁciency
and increased oxidative stress may have direct effects on the
differentiation and activity of bone cells. Decreased ATP
synthesis may disturb purinergic signaling, which has been
implicated in several signaling pathways involved in the
regulation of bone metabolism,(39) such as the response to
mechanical strain(40) and potentiation of PTH signaling.(41) DM,
myopathy, low body weight, and exercise intolerance may have
secondary effects on the bone phenotype, either by endocrine
regulation such as decreased secretion of myokines or lower
mechanical loading of the bone. Therefore, it would appear that
Table 5. Association Between Bone Turnover Markers and
Mutation Status
Model 1 Model 2 Model 3
N-terminal propeptide of type 1 procollagen (mg/L) (n¼ 78)
m.3243A>G (þ/–) –0.774 –0.760 –0.895
Diabetes (þ/–)a –0.691
C-terminal telopeptide of type 1 collagen (mg/L) (n¼ 72)
m.3243A>G (þ/–) –0.703 –0.741 –0.976
Diabetes (þ/–)a –0.552
Model 1: m.3243A>G status as independent variables. Model 2:
m.3243A>G status, weight, age, and gender as independent variables.
Model 3: m.3243A>G status, weight, age, gender, and DM status as
independent variables.
aIndependent effect of diabetes.
p< 0.05.
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the pathogenesis of the bone phenotype observed inm.3243A>G
is caused by a complex interplay of factors as illustrated in
Fig. 2.
The foremost limitation to this study is the inadequate
matching of cases and controls with regard to body weight. This
was particularly challenging because the variation in body
weight was substantial in cases, which comprised several
individuals with a low BMI. However, recruitment of healthy
individuals with a low BMI as controls was considered
inappropriate because underweight is infrequent in the normal
population and often associated with chronic conditions that
could have direct effects on bone. Furthermore, we abstained
frommatching diabetic cases with diabetic controls because DM
observed in m.3243A>G is different from T1D and T2D. The
coexistence of DM-inﬂuenced bone turnover, however,
omitting m.3243A>G carriers with manifest DM would have
excluded cases with the highest degree of mitochondrial
dysfunction, which were most likely to have developed a
distinct bone phenotype. Furthermore, we cannot exclude the
possibility that selection bias was introduced because controls
were recruited from urban population listings and controls from
both urban and rural parts of the country.
Acknowledging the shortcoming with regard to matching
on body weight, the present study has a number of strengths.
Most notably, we included a sizable number of individuals
with a rare mutation as well as age- and gender-matched
controls. Although validated methods were used to study
the bone phenotype in these rare cases, assessment of
dynamic bone histomorphometry could have provided
knowledge on the effects of mitochondrial dysfunction on
bone remodeling, including osteoblast and osteoclast activity
in humans.
In conclusion, this study shows that the m.3243A>G
mutation is associated with a bone phenotype characterized
by impaired bone mass, structure, and strength. Although the
mechanisms by which mitochondrial dysfunction affects bone
remodeling in humans cannot be determined by this study,
we speculate that enhanced oxidative stress and decreased
ATP production could lead to a premature ageing of the
skeleton.
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